FDA approved an expansion to the Imbruvica (ibrutinib) prescribing information based on data supporting its use in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
